CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising Eptinezumab and LuAG09222 wherein Eptinezumab comprises the VH region as defined in SEQ ID NO.: 4 and the VL as defined in SEQ ID NO.: 10, and LU AG09222 comprises the VH region as defined in SEQ ID NO.: 15 and the and VL region as defined in SEQ ID NO.: 20.
2. The pharmaceutical composition **of claim 1** which is formulated so as to maintain the biologic activity and/or storage stability of the Eptinezumab and LuAG09222 antibodies therein.
3. The pharmaceutical composition **of claim 1 or 2**, which maintains the biologic activity and/or storage stability of the Eptinezumab and LuAG09222 antibodies therein for at least 1 month, at least 2 months, at least 3 months, at least 3-6 months, at least 6-9 months, at least 9-12 months, or at least a year.
4. The pharmaceutical composition **according to any of the previous claims**, which comprises or further comprises histidine and either polysorbate 80 or poloxamer 188.
5. The pharmaceutical composition according to any of the previous claims which comprises or further comprises one, two or all of the following excipients NaCl, sorbitol and arginine.
6. The pharmaceutical composition **according to any of the previous claims**, which comprises a total concentration of Eptinezumab and LuAG09222 of 100 mg/mL to 300 mg/mL.
7. The pharmaceutical composition **according to any of the previous claims** which comprises a total concentration of Eptinezumab and LuAG09222 of about 100 mg/mL, about 150 mg/mL, about 200 mg/mL, about 250 mg/mL or about 300 mg/mL.
8. The pharmaceutical composition **according to claim 6 or 7** which comprises a ratio of Eptinezumab to LuAG09222 of about 1:1, 1:2 or 2:2.
9. The pharmaceutical composition **according to any of the previous claims** wherein the composition comprises about 100-300 mg/mL of Eptinezumab and about 50 -100 mg/mL of LuAG09222.
10. The pharmaceutical composition **according to any one of the previous claims** wherein the composition comprises about 100 mg/mL of Eptinezumab and about 50 mg/mL of LuAG09222.
11. The pharmaceutical composition **according to any one of the previous claims**, wherein Eptinezumab and LuAG0922 are the only active ingredients in the composition.

12. The pharmaceutical composition **according to any one of the previous claims**, wherein histidine is in a concentration ranging between 10 – 50 mM, optionally about 20-40 mM, Poloxamer P188 ranging between 0.0025-0.0120 % w/v and polysorbate 80 0.005-0.05% w/v inclusive.
13. The pharmaceutical composition **according to any one of the previous claims**, wherein the concentration of NaCl is between about 10-150 mM, optionally about 30-70 mM, 50-250 mM sorbitol (optionally L-sorbitol), optionally about 90-180 mM sorbitol, and between 50-250 mM inclusive of arginine (optionally L-arginine).
14. The pharmaceutical composition **according to any one of the previous claims**, wherein the pH is between about 5.0-6.8 inclusive.
15. The pharmaceutical composition **according to any one of the previous claims**, wherein the pH is about 5.0, about 5.5, about 5.9, about 6.0, about 6.5 or about 6.8.
16. The pharmaceutical composition **according to any one of the previous claims**, which is suitable for intravenous administration or subcutaneous administration.
17. The pharmaceutical composition **according to any one of the previous claims**, comprising Eptinezumab and LuAG90222 in a ratio of about 2:1, about 1:1 or about 1:2 and comprises about 20-40 mM histidine buffer, about 90-180 mM of sorbitol, 0.0025-0.0120% w/v of Poloxamer P188, and 30-70 mM NaCl, and has a pH about 6, optionally about pH 5.9.
18. The pharmaceutical composition **according to any one of the previous claims**, comprising Eptinezumab and LuAG90222 in a ratio of 2:1 and further comprising about 25-35 mM histidine buffer, about 165-175 mM sorbitol, about 0.0025-0.010% w/v of Poloxamer P188, and about 25-35 mM NaCl, and has a pH about 6, optionally about pH 5.9.
19. The pharmaceutical composition **according to any one of the previous claims**, comprising Eptinezumab and LuAG90222 in a ratio of 1:1 and further comprising about 30-40 mM histidine buffer, about 130-140 mM sorbitol, about 0.005-0.010% w/v of Poloxamer P188, and about 45-55 mM NaCl, and has a pH about 6, optionally pH 5.9.
20. The pharmaceutical composition **according to any one of the previous claims**, Eptinezumab and LuAG90222 in a ratio of 1:2 and further comprising about 35-45 mM histidine buffer, about 90-100 mM sorbitol, about 0.010-0.0120 % w/v of Poloxamer P188, and about 65-75 mM NaCl, and has a pH about 6, optionally pH 5.9.
21. The pharmaceutical composition **according to any one of the previous claims** for use as

a medicament.

22. Use of the pharmaceutical composition **according to any one of the previous claims** in the manufacture of a medicament for treating or preventing headache, optionally chronic or episodic migraine or cluster headache, further optionally wherein the administration of said pharmaceutical composition comprising said antibody combination has an additive or synergistic effect on the inhibition, alleviation or prevention of the number of, duration, and/or the intensity of migraine episodes compared to the subcutaneous or intravenous administration of a pharmaceutical composition comprising the same dosage of Eptinezumab or LuAG09222 alone.
23. Use of the pharmaceutical composition **according to any one of the previous claims** in the manufacture of a medicament for treating or preventing pain, optionally any of acute pain, chronic pain, neuropathic pain, nociceptive pain, and/or radicular pain, further optionally wherein the administration of said pharmaceutical composition comprising said antibody combination has an additive or synergistic effect on the inhibition or alleviation of pain, compared to the subcutaneous or intravenous administration of a pharmaceutical composition comprising the same dosage of Eptinezumab or LuAG09222 alone.
24. The pharmaceutical composition **according to any one of claims** 1-21 or the use according to claims 22-23, wherein the pharmaceutical composition is to be administered every month (every 4 weeks) or every 2 weeks.
25. The pharmaceutical composition **according to any one of claims** 1-21 or the use according to claims 22-23, wherein Eptinezumab comprises the heavy chain as defined in SEQ ID NO.: 5 or SEQ ID NO.: 6 and the light chain as defined in SEQ ID NO.: 11.
26. The pharmaceutical composition **according to any one of claims** 1-21, or the use according to claims 22-23, wherein LUAG09222 comprises the heavy chain as defined in SEQ ID NO.: 16 or SEQ ID NO.: 26 and the light chain as defined in SEQ ID NO.: 21.
27. Use of an antibody combination comprising Eptinezumab and LuAG09222 antibodies, wherein Eptinezumab comprises the VH region as defined in SEQ ID NO.: 4 and the VL as defined in SEQ ID NO.: 10, and LU AG09222 comprises the VH region as defined in SEQ ID NO.: 15 and the and VL region as defined in SEQ ID NO.: 20, in the manufacture of a medicament for treating or preventing headache, optionally chronic or episodic migraine or cluster headache,

    wherein the antibody combination is to be administered subcutaneously or

intravenously, and optionally

wherein the administration of said antibody combination has an additive or synergistic effect on the inhibition, alleviation or prevention of the number of, duration, and/or the intensity of migraine episodes compared to the subcutaneous or intravenous administration of the same dosage Eptinezumab or LuAG09222 alone.

28. Use of an antibody combination comprising Eptinezumab and LuAG09222 antibodies, wherein Eptinezumab comprises the VH region as defined in SEQ ID NO.: 4 and the VL as defined in SEQ ID NO.: 10, and LU AG09222 comprises the VH region as defined in SEQ ID NO.: 15 and the and VL region as defined in SEQ ID NO.: 20, in the manufacture of a medicament for treating or preventing pain, optionally any of acute pain, chronic pain, neuropathic pain, nociceptive pain, and/or radicular pain,

    wherein the antibody combination is to be administered subcutaneously or intravenously, and optionally

    wherein the administration of said antibody combination has an additive or synergistic effect on the inhibition or alleviation of pain, compared to the subcutaneous or intravenous administration of the same dosage of Eptinezumab or LuAG09222 alone.

29. The use **of claim 27 or 28**, wherein the Eptinezumab and LuAG09222 antibodies are to be administered subcutaneously or intravenously by administration of a pharmaceutical composition **according to any one of claims 1-20**.